Necrobiotic xanthogranuloma associated with smoldering multiple myeloma: satisfactory response to cyclophosphamide, dexamethasone, and thalidomide

An Bras Dermatol. 2019 Jul 29;94(3):337-340. doi: 10.1590/abd1806-4841.20198500.

Abstract

Necrobiotic xanthogranuloma is a rare chronic condition, belonging to the group C non-Langerhans cell histiocytoses, which is relevant due to the possibility of extracutaneous involvement and association with systemic diseases, particularly hematologic malignancies. The case reported here was only diagnosed after nine years of evolution and was associated with plasma cell dyscrasia. After treatment with cyclophosphamide, dexamethasone, and thalidomide, there was a reduction of cutaneous lesions and serum levels of monoclonal protein.

Publication types

  • Case Reports

MeSH terms

  • Cyclophosphamide / therapeutic use
  • Dexamethasone / therapeutic use
  • Female
  • Humans
  • Immunosuppressive Agents / therapeutic use
  • Middle Aged
  • Necrobiotic Xanthogranuloma / complications
  • Necrobiotic Xanthogranuloma / drug therapy*
  • Necrobiotic Xanthogranuloma / pathology
  • Smoldering Multiple Myeloma / complications
  • Smoldering Multiple Myeloma / drug therapy*
  • Smoldering Multiple Myeloma / pathology
  • Thalidomide / therapeutic use
  • Treatment Outcome

Substances

  • Immunosuppressive Agents
  • Thalidomide
  • Dexamethasone
  • Cyclophosphamide